MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
29.04
-2.93 (-9.16%)
At close: Apr 28, 2026, 4:00 PM EDT
29.00
-0.04 (-0.14%)
Pre-market: Apr 29, 2026, 6:46 AM EDT

MBX Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
19.210.986.983.86
Research & Development
78.8657.2228.3321.3
Operating Expenses
98.0668.1935.3125.16
Operating Income
-98.06-68.19-35.31-25.16
Interest Expense
----0.37
Interest & Investment Income
7.473.341.70.35
Other Non Operating Income (Expenses)
----0.07
EBT Excluding Unusual Items
-90.58-64.85-33.61-25.26
Gain (Loss) on Sale of Investments
3.612.931.040.03
Other Unusual Items
----0.9
Pretax Income
-86.97-61.92-32.56-26.14
Net Income
-86.97-61.92-32.56-26.14
Net Income to Common
-86.97-61.92-32.56-26.14
Shares Outstanding (Basic)
371111
Shares Outstanding (Diluted)
371111
Shares Change (YoY)
243.01%944.70%52.73%-
EPS (Basic)
-2.38-5.82-31.96-39.18
EPS (Diluted)
-2.38-5.82-31.96-39.18
Free Cash Flow
-81.88-55.56-32.11-23.56
Free Cash Flow Per Share
-2.24-5.22-31.52-35.33
EBITDA
-97.81-67.95-35.15-25.11
D&A For EBITDA
0.250.240.160.06
EBIT
-98.06-68.19-35.31-25.16
Source: S&P Capital IQ. Standard template. Financial Sources.